Ubs Group Ag Reneo Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Reneo Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 1,189 shares of RPHM stock, worth $1,997. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,189

Previous 11,192 89.38%

Holding current value

$1,997

Previous $16,000 87.5%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.34 - $1.7 $13,404 - $17,005	-10,003 Reduced 89.38%	1,189 $2,000
Q2 2024 Aug 13, 2024	SELL	$1.51 - $1.9 $1,031 - $1,297	-683 Reduced 5.75%	11,192 $16,000
Q1 2024 May 13, 2024	SELL	$1.59 - $1.74 $7,272 - $7,958	-4,574 Reduced 27.81%	11,875 $19,000
Q4 2023 Feb 09, 2024	SELL	$1.34 - $8.43 $16,440 - $103,427	-12,269 Reduced 42.72%	16,449 $26,000
Q3 2023 Nov 09, 2023	SELL	$5.44 - $8.13 $189,540 - $283,265	-34,842 Reduced 54.82%	28,718 $218,000
Q2 2023 Aug 11, 2023	BUY	$5.44 - $10.5 $57,658 - $111,289	10,599 Added 20.01%	63,560 $416,000
Q1 2023 May 12, 2023	SELL	$2.44 - $6.42 $11,189 - $29,442	-4,586 Reduced 7.97%	52,961 $316,000
Q4 2022 Feb 08, 2023	SELL	$1.8 - $3.52 $90 - $176	-50 Reduced 0.09%	57,547 $134,000
Q3 2022 Nov 10, 2022	BUY	$2.35 - $4.85 $7,160 - $14,777	3,047 Added 5.59%	57,597 $193,000
Q2 2022 Aug 10, 2022	BUY	$1.96 - $3.04 $104,826 - $162,588	53,483 Added 5012.46%	54,550 $145,000
Q1 2022 May 16, 2022	SELL	$2.94 - $9.07 $4,689 - $14,466	-1,595 Reduced 59.92%	1,067 $3,000
Q4 2021 Feb 14, 2022	BUY	$6.07 - $9.68 $16,158 - $25,768	2,662 New	2,662 $23,000

Others Institutions Holding RPHM

# of Institutions

Shares Held

21.5M

Call Options Held

50.8K

Put Options Held

View Full List

About Reneo Pharmaceuticals, Inc.

Ticker RPHM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,479,600
Market Cap $41.1M
Description
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as w...

More about RPHM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account